CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Vicore Pharma Holding AB (VCRE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Vicore Pharma Holding AB (VCRE)

Biotechnology · market cap $4.6B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-05-05
Other
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Vicore Pharma Holding AB (VCRE) is a 40-employee biotechnology company. Our database lists C21 as the lead asset (Phase 3, COVID-19) and Buloxibutid (Phase 2, Idiopathic Pulmonary Fibrosis) as the other pipeline program. The only dated event on our calendar is an estimated 2027-05-15 Phase 2 catalyst for Buloxibutid, which we rate 7/10 in importance. The company description, mechanism, and balance-sheet data are not in our data.
The catalyst path
  • 2027-05-05Otherimp 1/10
  • 2027-05-15 (est.)Phase 2 · Buloxibutidimp 7/10
Pipeline
AssetPhaseIndication
BuloxibutidPhase 2Idiopathic Pulmonary Fibrosis (IPF)
C21Phase 3COVID-19
Price & technical context
3-month
-16.9%
6-month
—
12-month
—
52-wk range
$8.66–$16.25
vs 50-day MA
+2.5%
vs 200-day MA
—
Realized vol
55.0%
Max drawdown
-46.7%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for VCRE (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.